{"status":"success","data":{"title":"Thyroid Storm - Treatment Strategies","slug":"thyroid-storm","tags":["propylthiouriacil","methimazole","propranolol","hydrocortisone","esmolol","cholestyramine"],"collection":["Endocrinology","Critical Care"],"content":"<h1 id=\"thyroid-storm-treatment-strategies\">Thyroid Storm: Treatment Strategies</h1>\n<p><strong>Take Home Points</strong></p>\n<ul>\n<li>Endocrinologic emergencies are too easily labeled as “sepsis”, as they can present very similarly. </li>\n<li>A <a href=\"http://www.medicalcriteria.com/site/index.php?option=com_content&amp;view=article&amp;id=262%3Aendts&amp;catid=52%3Aendocrinology-and-metabolism&amp;Itemid=80&amp;lang=en\">scoring system</a> developed by Burch and Wartofsky can assist in determining the likelihood of thyroid storm in patients based on presenting signs and symptoms. </li>\n<li>A previous <a href=\"http://academiclifeinem.com/diagnosing-hyperthyroidism/\">ALiEM blog post</a> further discusses some of the nuances associated with the diagnosis of thyroid storm.</li>\n</ul>\n<p><strong>You can think of the mainstay treatment strategies of thyroid storm based on three main goals:</strong></p>\n<ol>\n<li>Block the production and release of thyroid hormone </li>\n<li>Block the sympathetic outflow </li>\n<li>Block peripheral conversion of T4 to T3 </li>\n</ol>\n<p><strong>Click <a href=\"http://academiclifeinem.com/thyroid-storm-treatment-strategies/\">here</a> for full ALiEM blog post</strong></p>\n<h2 id=\"thionamides\">THIONAMIDES</h2>\n<ul>\n<li>Mechanism of action: Inhibit thyroid peroxidase, an enzyme involved in the production of T3 and T4 through the iodination of tyrosine residues on thyroglobulin</li>\n<li>Agents: <span class=\"drug\">propylthiouriacil</span> (PTU) and <span class=\"drug\">methimazole</span> (MMI)</li>\n<li>Dosing<ul>\n<li><strong>PTU</strong><ul>\n<li>Loading dose: 600 to 1000 mg PO</li>\n<li>Maintenance dose: 200 to 250 mg PO q4h</li>\n</ul>\n</li>\n<li><strong>MMI</strong><ul>\n<li>Loading dose: 20 to 25 mg</li>\n<li>Maintenance dose: 20 to 25 mg PO q4h</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<!-- -->\n<ul>\n<li>No head-to-head trials have shown any benefit of using one thionamide over another in the management of thyroid storm</li>\n<li>Additional benefit of <span class=\"drug\">PTU</span> in thyroid storm:<ul>\n<li>Inhibition of the peripheral conversion of T4 to T3 (3rd “B”)</li>\n</ul>\n</li>\n<li>Alternative routes of administration:<ul>\n<li><span class=\"drug\">PTU</span> and <span class=\"drug\">MMI</span> can both be administered through the rectal route as a suppository and retention enema<ul>\n<li>Shown to have good response in several trials [<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3410604\">Bartle (1988)</a>, <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=21254909\">Alfadhi (2011)</a>]</li>\n</ul>\n</li>\n<li>Intravenous (IV) thionamides are currently not commercially available in the United States<ul>\n<li>IV formulation of MMI is available in Europe</li>\n<li>Success reported in case reports and case series of treating thyroid storm with IV MMI compounded formulations [<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=3224594\">Sowinski (1988)</a>, <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16889494\">Hodak (2006)</a>, <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8435884\">Solomon (1993)</a>]</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Pregnancy considerations:<ul>\n<li><span class=\"drug\">PTU</span> is generally preferred over <span class=\"drug\">MMI</span></li>\n</ul>\n</li>\n<li>Adverse effects:<ul>\n<li><span class=\"drug\">PTU</span>: black box warning for severe and/or life-threatening hepatotoxicity issued by FDA in 2010</li>\n<li>Agranulocytosis:<ul>\n<li>Can occur at any point during treatment</li>\n<li>Tends to be dose-related with MMI, unlike PTU</li>\n<li>Granulocyte colony-stimulating factors (G-CSFs) can be used in the management of thionamide-induced agranulocytosis</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"inorganic-iodine\">INORGANIC IODINE</h2>\n<ul>\n<li>Used to prevent the release of pre-formed thyroid hormone from the thyroid gland</li>\n<li>Various formulations:<ul>\n<li><strong>Saturated solution of potassium iodide (SSKI)</strong>: 5 drops PO, NG, or PR q6h</li>\n<li><strong>Lugol’s solution:</strong> 8 drops PO, NG, or PR q6h</li>\n<li><strong>Sodium iodide:</strong> 500 mg IV q12h </li>\n</ul>\n</li>\n<li>Administration of inorganic iodine should be delayed for at least one hour after initiation of thionamide therapy</li>\n<li><span class=\"drug\">Iodine</span> load can serve as a substrate for thyroid hormone synthesis and exacerbate thyroid storm</li>\n<li><span class=\"drug\">Iodine</span> content of formations (NOTE: Solutions <strong>are not interchangeable</strong>.)</li>\n</ul>\n<table>\n<thead>\n<tr>\n<th>Iodine Solution</th>\n<th>Content of Iodine Per Drop</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>SSKI</td>\n<td>38 mg iodine</td>\n</tr>\n<tr>\n<td>Lugol&#39;s Solution</td>\n<td>8 mg iodine</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>The dose is by the <strong>dropperful</strong> (as opposed to mL) of solution</li>\n<li>Dissolve the dose in solution of 3 to 4 ounces of milk, fruit juice, or water to ensure that the full dose is given and to mask the bitter taste</li>\n<li>If true allergy to iodine or contraindication to iodine therapy (e.g. <span class=\"drug\">amiodarone</span>-induced thyrotoxicosis):<ul>\n<li>Consider administration of <span class=\"drug\">lithium</span> carbonate 300 mg PO or NG q6h</li>\n<li>Maintain <span class=\"drug\">lithium</span> level within range of 0.8 to 1.2 mEq/L</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"beta-blockade\">BETA BLOCKADE</h2>\n<ul>\n<li>Enhanced α- and β-adrenergic stimulation in the setting of thyroid storm leads to clinical manifestations</li>\n<li><p><strong><span class=\"drug\">Propranolol</span>:</strong> most commonly used agent</p>\n<ul>\n<li>Inhibits peripheral conversion of T4 to T3 (3nd “B”)<ul>\n<li>Effect not demonstrated considerably with other β-antagonists</li>\n</ul>\n</li>\n<li>Blocks non-selective β-adrenergic receptors to allow for effective treatment of systemic effects, such as tremor, tachycardia, agitation, fever, diaphoresis, psychosis (2nd “B”)</li>\n<li>Dose: 60 to 80 mg PO q4h<ul>\n<li>Proper dosing of <span class=\"drug\">propranolol</span> is essential because of dose-dependent effects on inhibition of peripheral conversion of thyroid hormone (&gt; 160 mg/day), and rapid metabolism of the agent in the setting of thyroid storm</li>\n</ul>\n</li>\n<li>Alternative route of <span class=\"drug\">propranolol</span>: IV formulation (determine availability at your institution)</li>\n<li>Two-step method for administration:</li>\n</ul>\n<ol>\n<li>Test dose: 0.5 to 1 mg as slow IV push administered over 10 minutes</li>\n<li>Subsequent doses: 1 to 3 mg IV over 10 to 15 minutes every few hours to desired effect with monitoring of cardiac rhythm</li>\n</ol>\n</li>\n<li><strong><span class=\"drug\">Esmolol</span></strong> can be considered as an alternative agent</li>\n<li>Contraindications to beta blockade: guanethidine or reserpine with close monitoring for hypotension</li>\n</ul>\n<h2 id=\"corticosteroids\">CORTICOSTEROIDS</h2>\n<ul>\n<li>Depression of the hypothalamic-pituitary axis commonly occurs in the setting of thyroid storm</li>\n<li>Additional benefit: inhibition of peripheral conversion of T4 to T3 (3rd “B”)</li>\n<li><strong><span class=\"drug\">Hydrocortisone</span></strong>: loading dose of 300 mg IV followed by maintenance dose of 100 mg IV q8h (or dose equivalent)</li>\n</ul>\n<h2 id=\"other-therapies\">OTHER THERAPIES</h2>\n<ul>\n<li><strong><span class=\"drug\">Cholestyramine</span> resin:</strong><ul>\n<li>Can be used to interrupt enterohepatic recirculation of thyroid hormone, leading to decreased circulating levels of thyroid hormone [<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=7054215\">Nabil (1982)</a>, <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8784067\">Mercado (1996)</a>]</li>\n<li>Dose: 4 g PO q6h</li>\n</ul>\n</li>\n<li><strong>Supportive measures</strong><ul>\n<li>Fluid resuscitation</li>\n<li>Dissipation of heat with various cooling modalities for hyperthermia control</li>\n<li>Benzodiazepines for control of agitation and to minimize sympathetic outflow</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=3224594\">Sowinski J, Junik R, Gembicki M. Effectiveness of intravenous administration of methimazole in patients with thyroid crisis. Endokrynol Pol 1988; 39:67-73.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16889494\">Hodak SP, Huang C, Clarke D, et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 2006; 16:691-695.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8435884\">Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol 1993;38:39-43.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8784067\">Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, et al. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 1996; 81:3191-3193.</a></li>\n<li><a href=\"Mercado%20M,%20Mendoza-Zubieta%20V,%20Bautista-Osorio%20R,%20et%20al.%20Treatment%20of%20hyperthyroidism%20with%20a%20combination%20of%20methimazole%20and%20cholestyramine.%20J%20Clin%20Endocrinol%20Metab%201996;%2081:3191-3193.%20\">Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263-277.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3410604\">Bartle WR, Walker SE, Silverberg JD. Rectal absorption of propylthiouracil. Int J Clin Pharmacol Ther Toxicol 1988; 26:285-287.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=21254909\">Alfadhli E, Gianoukakis AG. Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid 2011; 21:215-220.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=7054215\">Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180-181.</a></li>\n</ul>\n"}}